{"id":"folfox4-or-xelox","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"15-25","effect":"Hand-foot syndrome (XELOX)"}]},"_chembl":{"chemblId":"CHEMBL5970128","moleculeType":null,"molecularWeight":"607.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX4 combines 5-fluorouracil (5-FU), leucovorin, and oxaliplatin; XELOX substitutes oral capecitabine for intravenous 5-FU. Both regimens work synergistically: 5-FU/capecitabine inhibit thymidylate synthase to disrupt DNA synthesis, while oxaliplatin forms DNA cross-links. These agents target rapidly dividing cancer cells across multiple phases of the cell cycle.","oneSentence":"FOLFOX4 and XELOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:14.758Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Adjuvant treatment of stage III colorectal cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT02355379","phase":"PHASE3","title":"Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-01","conditions":"Colonic Adenocarcinoma","enrollment":774},{"nctId":"NCT00958737","phase":"PHASE3","title":"Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2009-05-12","conditions":"Colorectal Cancer","enrollment":2000},{"nctId":"NCT02934464","phase":"PHASE3","title":"Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2016-12","conditions":"Stomach Neoplasms","enrollment":280},{"nctId":"NCT04690283","phase":"PHASE3","title":"Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2021-01-01","conditions":"Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer","enrollment":360},{"nctId":"NCT01308086","phase":"PHASE3","title":"Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer","status":"UNKNOWN","sponsor":"Hellenic Oncology Research Group","startDate":"2010-10","conditions":"CRC","enrollment":2000},{"nctId":"NCT00646607","phase":"PHASE3","title":"FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer","status":"COMPLETED","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2007-06","conditions":"Colon Cancer","enrollment":3756},{"nctId":"NCT00112918","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-12","conditions":"Colorectal Cancer","enrollment":3451},{"nctId":"NCT01087658","phase":"PHASE3","title":"Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Colorectal Neoplasms","enrollment":200},{"nctId":"NCT00349336","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-08","conditions":"Colorectal Cancer","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1500,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FOLFOX4 or XELOX","genericName":"FOLFOX4 or XELOX","companyName":"Federation Francophone de Cancerologie Digestive","companyId":"federation-francophone-de-cancerologie-digestive","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX4 and XELOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}